The development and progress of nanomedicine for esophageal cancer diagnosis and treatment
The development and progress of nanomedicine for esophageal cancer diagnosis and treatment
复制标题
DOI：
10.1016/j.semcancer.2022.01.007
复制
发表时间：
2022-10-18
影响因子：
14.5
通讯作者：
Yuan，Yong
中科院分区：
文献类型：
--
作者：
Li，Xiaokun;Chen，Lingmin;Yuan，Yong
食管癌是一种常见的胃肠道恶性肿瘤，预后差，死亡率高。虽然联合治疗策略已经开发，与EC患者的5年生存率仍然相对较差。传统的抗癌药物传递技术存在一些缺点，如非靶向传递和非特异性毒性。纳米粒子（Nanoparticles，NPs）为EC的各种治疗方式提供了一个有前途的药物递送平台，它在癌症治疗中具有几个显着的优势，如减少副作用，延长循环时间，并优先在肿瘤部位积聚。本文综述了近年来应用于食管癌治疗的纳米粒子，包括聚合物、胶束、脂质体、无机纳米粒子和有机纳米粒子。同时，我们讨论了新设计的纳米药物在各种治疗EC，包括化疗，放疗，基因治疗，光动力治疗（PDT），光热治疗（PTT），以及它们的协同治疗的有效性和安全性。此外，还对纳米医学在肿瘤成像和诊断中的应用进行了综述。目前的研究表明，纳米制剂的潜在优势超过传统制剂。未来将有更多的研究来促进纳米药物在EC中的临床转化。
Esophageal cancer (EC) is a common gastrointestinal malignancy with poor prognosis and high mortality. Although combined therapeutic strategies have been developed, the 5-year survival rate of patients with EC remains relatively poor. Conventional anti-cancer drug delivery techniques have some shortcomings, such as nontargeted delivery and nonspecific toxicity. Nanoparticles (NPs) provide a promising platform for delivering drugs in various therapeutic modalities for EC, which possess several remarkable advantages in cancer therapy, such as reduced side effects, prolonged circulation time, and preferential accumulation at the tumor site. In this review, we summarized various types of NPs applied in the treatment of EC, including polymers, micelles, liposomes, inorganic NPs and organic NPs. Meanwhile, we discussed the efficacy and safety of newly designed nanomedicine in various treatments of EC, including chemotherapy, radiotherapy, gene therapy, photodynamic therapy (PDT), photothermal therapy (PTT), and their synergetic therapy. In addition, nanomedicine applied in tumor imaging and diagnoses were also reviewed. Current studies have suggested the potential advantages of nanoformulations over conventional formulations. More researches to promote clinical translation of nanomedicine for EC are anticipated in the future.